WaveMan
WaveMan · Company
INM · Inmed Pharmaceuticals Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

INM InMed Pharmaceuticals (INM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001728328
Quote by TradingView
Cluster · 3 insidersActivist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter

What the filings say about INM

Insiders, 180 days
+$1.4M net bought
3 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 21.7% of the class

InMed Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, InMed Pharmaceuticals Inc. insiders bought a net $1.4M of stock across 61 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
ADAR1 Capital Management, LLC
BUY
2026-10-27 SECtraded 2026-10-23
4
$5
n/a
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Oct 19, 2026.
  • The trade is 0.0% of the 956,584 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $5 of INM on Oct 23, 2026; 13 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-10-20 SECtraded 2026-10-19
1,086
$1.4K
+16.9%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Oct 16, 2026.
  • The trade is 0.1% of the 956,580 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $1.4K of INM on Oct 19, 2026; 13 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-10-20 SECtraded 2026-10-16
1
$1
+16.9%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Oct 15, 2026.
  • The trade is 0.0% of the 955,494 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $1 of INM on Oct 16, 2026; 13 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-10-15 SEC
984
$1.3K
+20.5%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Oct 14, 2026.
  • The trade is 0.1% of the 955,493 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $1.3K of INM on Oct 15, 2026; 13 funds added in the latest 13F quarter.
ADAR1 Capital Management, LLC
BUY
2026-10-15 SECtraded 2026-10-14
8,021
$10.7K
+20.5%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Oct 13, 2026.
  • The trade is 0.8% of the 954,509 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider ADAR1 Capital Management, LLC bought about $10.7K of INM on Oct 14, 2026; 13 funds added in the latest 13F quarter.
61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 56 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.4M over 180 days
+$203.8K over 90 days · +$1.4M of it by a 10%+ holder
more than 90% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
+7.5% year over year
more than 56% of Pharma & Biotech
Margin
-254.1% net margin
below 69% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 78% of Pharma & Biotech
The situation: each line is one rule over one dataset
Vivo Opportunity Fund Holdings, L.P. disclosed a 5%+ stake (21.7%) in the last six months.
What changed in the last 30 days
Oct 27Insider ADAR1 Capital Management, LLC bought $85.7K (12 trades, Oct 1 to Oct 23)

Watch INM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-21.7%12M
-70%-46%-22%+2%2025-102025-122026-022026-042026-062026-082026-10 2026-05-19 · Schneeberger Daniel bought $312.0K2026-05-19 · Schneeberger Daniel bought $300.0K2026-05-19 · Schneeberger Daniel bought $109.7K2026-05-20 · Vivo Opportunity, LLC bought $79.6K2026-06-05 · Vivo Opportunity, LLC bought $78.4K2026-09-15 · ADAR1 Capital Management, LLC bought $70.4K2026-05-21 · Vivo Opportunity, LLC bought $52.2K2026-06-08 · Vivo Opportunity, LLC bought $44.9K2026-09-14 · ADAR1 Capital Management, LLC bought $36.9K2026-06-02 · Vivo Opportunity, LLC bought $31.5K2026-05-29 · Vivo Opportunity, LLC bought $25.4K2026-10-05 · ADAR1 Capital Management, LLC bought $24.2K2026-06-01 · Vivo Opportunity, LLC bought $23.0K2026-10-01 · ADAR1 Capital Management, LLC bought $21.8K2026-07-15 · Vivo Opportunity, LLC bought $21.3K2026-10-02 · ADAR1 Capital Management, LLC bought $11.0K2026-06-03 · Vivo Opportunity, LLC bought $11.0K2026-09-16 · ADAR1 Capital Management, LLC bought $10.8K2026-10-14 · ADAR1 Capital Management, LLC bought $10.7K2026-06-04 · Vivo Opportunity, LLC bought $9.6K2026-05-20 · Vivo Opportunity, LLC bought $8.0K2026-06-05 · Vivo Opportunity, LLC bought $7.9K2026-07-14 · Vivo Opportunity, LLC bought $7.6K2026-10-06 · ADAR1 Capital Management, LLC bought $7.4K2026-07-01 · Vivo Opportunity, LLC bought $6.1K2026-05-21 · Vivo Opportunity, LLC bought $5.3K2026-06-08 · Vivo Opportunity, LLC bought $4.5K2026-10-07 · ADAR1 Capital Management, LLC bought $4.1K2026-06-02 · Vivo Opportunity, LLC bought $3.2K2026-10-08 · ADAR1 Capital Management, LLC bought $3.0K2026-05-29 · Vivo Opportunity, LLC bought $2.6K2026-06-01 · Vivo Opportunity, LLC bought $2.3K2026-07-02 · Vivo Opportunity, LLC bought $2.3K2026-07-15 · Vivo Opportunity, LLC bought $2.2K2026-07-15 · ADAR1 Capital Management, LLC bought $1.6K2026-10-19 · ADAR1 Capital Management, LLC bought $1.4K2026-10-15 · ADAR1 Capital Management, LLC bought $1.3K2026-06-03 · Vivo Opportunity, LLC bought $1.1K2026-06-04 · Vivo Opportunity, LLC bought $9702026-06-30 · Vivo Opportunity, LLC bought $8392026-07-14 · Vivo Opportunity, LLC bought $7642026-10-13 · ADAR1 Capital Management, LLC bought $7502026-06-10 · Vivo Opportunity Fund Holdings, L.P. filed a 5%+ stake (21.7%)2026-06-10 · Vivo Opportunity, LLC filed a 5%+ stake (21.7%)2026-06-10 · Vivo Opportunity Cayman Fund, L.P. filed a 5%+ stake (2.2%)2026-06-10 · Vivo Opportunity Cayman, LLC filed a 5%+ stake (2.2%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns INM: institutional holders (13F)

13F holdings, latest reported quarter
ADAR1 Capital Management, LLC
800,000 sh
$1.2M
Vivo Capital, LLC
798,377 sh
$1.2M
Squadron Capital Management LLC
325,000 sh
$503.8K
Ikarian Capital, LLC
245,025 sh
$379.8K
Ursa Fund Management, LLC
125,800 sh
$195.0K

Congress trades in INM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Vivo Opportunity Fund Holdings, L.P.
Activist 13D · 2026-06-10
21.7%
Vivo Opportunity, LLC
Activist 13D · 2026-06-10
21.7%
Vivo Opportunity Cayman Fund, L.P.
Activist 13D · 2026-06-10
2.2%
Vivo Opportunity Cayman, LLC
Activist 13D · 2026-06-10
2.2%

INM planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

INM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Blackstone Alternative Multi-Strategy Fund
$10.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $1.4M bought by insiders over 180 days, 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

INM financials

Revenue growth
+7.5%
XBRL, annual
Net margin
-254.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.5M
four quarters, 2025-01-01 to 2025-12-31
Net margin, TTM
-278.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.03x
current debt only, 2022-03-31 (51 months older than the period end); equity 2026-06-30
Cash flow to debt
-294.88x
TTM operating cash flow over current debt only, 2022-03-31 (51 months older than the period end)
Return on equity
-173.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-135.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-94.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$3.6M
market value at close 2026-10-26 on 2026-09-02 shares, plus current debt only, 2022-03-31 (51 months older than the period end), minus cash 2026-03-31
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-06
Revenuen/a$4.9M$4.6M$4.1M
Gross profitn/a$1.7M$1.1M$1.4M
Operating incomen/an/an/a-$7.9M
Net income-$12.6M-$8.2M-$7.7M-$7.9M
EPS (diluted)-3.12-8.36-20.14-3.25
Operating cash flow-$8.6M-$8.1M-$7.0M-$7.3M
Cashn/a$10.7M$6.6M$8.9M
SEC XBRL, fiscal years, as known on 2026-10-28

INM Stock Sonar score 6/7 axes

Find similar shapesCompare

INM ranks highest on insider conviction (89th percentile) and risk and compliance (70th), and lowest on profitability (21st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
21
Inputs
  • Return on equity-173.1% · 19 pct, sector of 545
  • Return on assets-135.0% · 18 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-94.1% · 27 pct, sector of 576
Financial health
37
Inputs
  • Debt to equity0.03x · 69 pct, sector of 352
  • Cash flow to debt-294.88x · 5 pct, sector of 371
Growth
56
Inputs
  • Revenue growth, YoY+7.5% · 56 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
89
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.4M · 90 pct, sector of 428
  • Insider buyers, 180d3 · 89 pct, sector of 437
Institutional and government
23
Inputs
  • Funds adding, latest quarter13 · 23 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
70
Inputs
  • Short interest, % of float+1.1% · 79 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.5% · 61 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

INM filings, in plain words

Are InMed Pharmaceuticals insiders buying or selling INM?

In the 180 days to 2026-10-28, InMed Pharmaceuticals insiders were net buyers, a net $1.4M across purchases and sales reported on Form 4, by 3 buyers.

Read the full summary

In the 180 days to 2026-10-28, InMed Pharmaceuticals insiders were net buyers of INM, a net $1.4M across purchases and sales reported on Form 4 by 3 buyers. Most of that figure, $1.4M, came from a holder of 10% or more rather than an officer or director. 3 insiders reported purchases in that window. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 21.7% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies